Introduction
============

Although infections are caused by many pathogens, in high-risk hospital units like intensive care units (ICUs), research has shown that infections resulting from *Staphylococcus aureus* are on the rise emerging as a major public health concern to staff and patients in recent years.^[@r1],[@r2]^ Methicillin-resistant *S. aureus* (MRSA) is a common nosocomial pathogen equipped with resistance and virulence factors which persist in hospitals and communities and can cause serious human and animal infections.^[@r3]^

Studies indicate a considerable proportion of resistance to many classes of antibiotics in clinical MRSA isolates.^[@r3]-[@r6]^ Many therapeutic options have been shown to be less effective for the treatment of MRSA infection because of the presence of multiresistant genes, which has resulted in clinical outcomes and increased morbidity and mortality rates.^[@r1],[@r2]^ There is an apparent association between the pathogenesis of MRSA strains and the expression of virulence factors such as cell surface components (e.g., collagen-binding protein, clumping factor, fibronectin-binding protein, and elastin-binding protein) and secreted factors (e.g., staphylokinase, toxic shock syndrome toxin-1, hemolysin, Panton-Valentine leukocidin (PVL), exfoliative toxins (eta, etb), staphylococcal enterotoxins, and lipase).^[@r3]^

The development and spread of multidrug resistance (MDR) among MRSA isolates have been caused by the widespread use of beta-lactam, aminoglycoside, macrolides, and lincosamides over the last few decades.^[@r7],[@r8]^ Aminoglycoside-modifying enzymes, including aminoglycoside phosphotransferase (APH), aminoglycoside acetyltransferase (AAC), and aminoglycoside nucleotidyltransferase, act as mediators in aminoglycoside resistance.^[@r5],[@r6]^ Resistance to macrolides is associated with three mechanisms: i) target modification (mediated by *erm* genes); ii) efflux pumps (mediated by *msr* genes); and iii) enzymatic modification (mediated by *lun* genes). *MupA* and *mupB* genes act as mediators in mupirocin resistance. Research has shown that vancomycin is effective against *S. aureus* strain-related infections, but MRSA strains have increased alarmingly in recent years, which has reduced vancomycin susceptibility.^[@r9]^ *VanA* and *vanB* genes act as mediators in vancomycin resistance.^[@r9],[@r10]^

Because of the increasing occurrence of *S. aureus* infections in ICU patients, awareness of the molecular and resistance patterns of this bacterium is imperative. Pulsed-field gel electrophoresis (PFGE), staphylococcal cassette chromosome *mec* (SCC*mec*) typing, accessory gene regulator (*agr*) typing, *mec*-associated hypervariable region (*dru*) typing, multilocus sequence typing (MLST), coagulase (*coa*) typing, and *spa* typing have been employed for typing *S. aureus* isolates.^[@r4],[@r7],[@r11]-[@r13]^ Although PFGE has been established as the standard method in recent years, it is believed that polymerase chain reaction (PCR)-based methods such as SCC*mec* and *spa* typing are ideal because of their cost-benefit, rapidity and high throughput capability.^[@r13]^ Three distinct regions (Fc, X, and C) are present in the *spa* gene. The polymorphic X region of the protein A gene has been sequenced by *spa* typing, which is a single-locus typing technique.^[@r8],[@r13]^

Although the *spa* type distribution of *S. aureus* strains varies by geographic location, data from Iran indicates that *spa* types t790, t030, and t037 are widely disseminated in *S. aureus* clinical isolates.^[@r4],[@r7],[@r8],[@r11]^ These also have been frequently reported in the Middle East, some European countries, and the United States.^[@r14],[@r15]^

Resistance to methicillin is mediated by the *mecA* gene, which is carried within SCC*mec*. SCC*mec* elements are categorized according to differences in structure through SCC*mec* typing. Eleven types of SCC*mec* (I-XI) have been categorized through the *mec* gene and *ccr* gene complexes.^[@r16]^

With this background, it could be said that controlling staphylococcal infections is better achieved by identifying antibiotic resistance patterns, carriage of resistance genes, virulence determinants, and molecular types of *S. aureus* strains isolated from ICUs.^[@r1],[@r9]^ We investigated the antibiotic resistance pattern, carriage of resistance and virulence determinants, and molecular typing of *S. aureus* isolates collected from ICUs based on *SCCmec* and *spa* genes.

Methods
=======

Our cross-sectional research study was conducted between March and December 2017. Five university hospitals were designated to collect 84 non-duplicated MRSA strains isolated from clinical samples from ICU patients. These samples were obtained at the request of the specialist for medical reasons. The most common samples for MRSA strain isolation were wounds (n = 40; 47.6%), blood (n = 19; 22.6%), pus (n = 17; 20.2%), and catheters (n = 8; 9.5%). Out of 17 pus samples, six were drained from postoperative abscesses, four from breast abscesses, three from prostatic abscesses, two from a spinal epidural abscess, one from a lung abscess, and one from a salivary gland abscess. The Ethics Committee of Shahid Beheshti University of Medical Sciences in Tehran, Iran (IR.SBMU.SM.REC.1396.412) approved the research.

Preliminary identification was done by routine laboratory methods (colony morphology such as shape, size, color and hemolysis patterns, gram staining, tube coagulase tests, production of catalase tests, mannitol fermentation, and DNase plates). The isolates were confirmed to be *S. aureus* by detection of the *femA* and *nucA* genes using PCR.^[@r6]^

Mueller-Hinton agar (Merck; Germany) plates were used for phenotypic screening of methicillin resistance using cefoxitin 30 µg discs. As recommended by the Clinical and Laboratory Standard Institute (CLSI), 4% sodium chloride was added as a supplement.^[@r17]^ The criterion for choosing an isolate to investigate the presence of *mecA* gene was the observance of phenotypic methicillin resistance. After confirming the isolates as MRSA, they were stored in tryptic soy broth (Merck; Germany) for molecular testing along with 20% glycerol at -70 °C.

The susceptibility of each isolate was determined by the disk diffusion method as recommended by CLSI,^[@r17]^ except for ceftriaxone and fusidic acid, which were used according to the European Committee for Antimicrobial Susceptibility Testing (EUCAST) guidelines. Briefly, the inoculum was prepared from pure colonies of bacterial overnight culture, which were suspended in broth media or saline to an optical density equivalent to a 0.5 McFarland standard. Afterwards, Mueller-Hinton agar plates were seeded with *S. aureus* using a sterile cotton swab. Eventually, antibiotic disks were placed on the agar surface, and the plate was incubated at 35 °C overnight. After incubation, the diameter of the growth inhibition zone was measured in millimeters and interpreted using CLSI guidelines.^[@r17]^ The following antimicrobial agents (Mast; UK) were investigated: penicillin, ceftriaxone, kanamycin, ciprofloxacin, rifampicin, clindamycin, quinupristin-dalfopristin, tetracycline, erythromycin, linezolid, teicoplanin, fusidic acid, amikacin, tobramycin, gentamicin, and trimethoprim-sulfamethoxazole. The minimum inhibitory concentration (MIC) for vancomycin and mupirocin were determined by the broth microdilution test as recommended by CLSI.^[@r17]^ As instructed by CLSI, the broth microdilution test was performed to measure the MIC for vancomycin and mupirocin. MIC values of 8--256 µg/mL and 512 µg/mL were set to indicate low-level and high-level mupirocin resistance (LLMUPR, HLMUPR) of the strains, respectively.

As recommended by the EUCAST, fusidic acid MIC values of ≤ 1 µg/mL and \> 1 µg/mL were set as signifying susceptible and resistant types, respectively. It is believed that, in addition to beta-lactams, MDR isolates cover resistance to three or more unique antibiotic classes.^[@r7],[@r11],[@r18]^ The standard strains for quality control were *S. aureus* ATCC25923 and ATCC29213.

The genomic DNA extraction for PCR assays was performed using the InstaGene matrix (BioRad; USA). This was done following manufacturer instructions with modifications such as the addition of 20 μL of 1 mg/mL lysostaphin (Sigma-Aldrich; USA). Isolates that exhibited phenotypic resistance to particular antimicrobial agents were tested for the presence of resistance genes (*mecA, vanA, vanB, mupB, mupA, erm(A), erm(B), erm(C), msr(A), msr(B), tet(M), ant* (4´)*-Ia, aac* (6´)*-Ie/aph* (2˝), *aph* (3´)*-IIIa*) using PCR.^[@r6],[@r11],[@r19]^ The carriage of genes that encode toxins such as *etb*, *eta*, *pvl* and *tst,* were examined using PCR as described.^[@r6],[@r11]^

MRSA isolates underwent *spa* typing as recommended by Harmsen et al.^[@r13]^ Purified *spa* PCR products were subjected for DNA sequencing for both strands by Macrogen (Macrogen; South Korea). The sequences obtained were edited using Chromas software (version 1.45; Australia). Edited sequences were assigned to specific *spa* types using the Ridom Spa Server database (<http://www.spaserver.ridom.de>).

Multiplex-PCR was performed to type the SCC*mec* elements using specific primers as described by Boye et al.^[@r16]^ The following strains were used as references: ATCC 10442 (SCC*mec* type I), N315 (SCC*mec* type II), 85/2082 (SCC*mec* type III), MW2 (SCC*mec* type IV), and WIS (SCC*mec* type V).

Statistical analysis was performed using SPSS Statistics (SPSS Inc. Released 2009. PASW Statistics for Windows, Version 18.0. Chicago: SPSS Inc).

Results
=======

All isolates were MRSA. The number of MRSA isolates isolated from each hospital was as follows: 21 (25.0%) from hospital A, 18 (21.4%) from hospital B, 14 (16.7%) from hospital C, 12 (14.3%) from hospital D, and 19 (22.6%) from hospital E. Based on the results of the antimicrobial susceptibility testing, all 84 isolates were susceptible to vancomycin, linezolid, teicoplanin, and fusidic acid.

Higher resistance rates were observed for penicillin (72.6%) followed by gentamicin (59.5%), ceftriaxone (57.1%), kanamycin (48.8%), ciprofloxacin (46.4%), erythromycin (46.4%), tetracycline (42.9%), clindamycin (35.7%), rifampin (33.3%), mupirocin (26.2%), amikacin (20.2%), tobramycin (15.5%), and quinupristin-dalfopristin (14.3%). Resistance-associated genes demonstrated that 63.1% of isolates harbored the *ant* (4´)-*Ia* gene followed by *aac* (6´)-*Ie/aph (*2˝) (53.6%), *aph* (3´)-*IIIa* (35.7%), *erm*(A) (22.6%), *tet*(M) (15.5%), *erm*(B) (14.3%), *msr*(A) (13.1%), *erm*(C) (11.9%), *msr*(B) (9.5%), and *mupA* (9.5%). All isolates were negative for genes encoding *vanA, vanB,* and *mupB*. Among the 84 MRSA isolates investigated, the most frequent toxin gene was *tst* (25.0%). A low frequency of toxin genes was noted in isolates with *pvl* (14.3%), *eta* (3.6%), and *etb* (2.4%) genes \[[Figure 1](#f1){ref-type="fig"}\].

![Lane M, 100-bp DNA Ladder (Fermentas, UK); Lane 1 *nucA* gene (270bp), Lane 2 *eta* gene (93bp), Lane 3 *etb* gene (276 bp), Lane 4 *tst-1* gene (398 bp), Lane 5 *luk-PV* gene (180 bp), Lane 6 *mecA* gene (583 bp), Lane 7 *tet(M)* gene (158 bp), Lane 8 *msr(A)* gene (940 bp), Lane 9 *msr(B)* gene (595 bp), Lane 10 *erm(A)* gene (139 bp), Lane 11 *erm(B)* gene (141 bp), Lane 12 *erm(C)* gene (299 bp), Lane 13 *ant(4´)-Ia* gene (135 bp), Lane 14 *aph(3´)-IIIa* gene (269 bp), Lane 15 *aac(6´)-Ie/aph(2˝)* gene (222 bp), and Lane 16 *mupA* gene (1158 bp).](OMJ-D-18-00070-f1){#f1}

Of the 84 MRSA isolates, 78.6% (66/84) were defined as MDR. The predominant simultaneous resistance patterns were for six antibiotics (17.9%, 15/84) followed by three antibiotics (13.1%, 11/84), seven antibiotics (11.9%, 10/84), nine antibiotics (10.7%, 9/84), and five antibiotics (6.0%, 5/84). Of the 22 mupirocin-resistant MRSA isolates, eight (9.5%) had high resistance levels, and 14 (16.7%) had low resistance levels. All the HLMUPR strains were collected from wound samples. Constitutive and inducible phenotypes were detected in 30 (35.7%) and 9 (10.7%) MRSA isolates, respectively.

SCC*mec* typing showed that type III was predominant and present in 50 isolates (59.5%), followed by type IV in 34 isolates (40.5%). The *spa* typing discriminated seven types: t388 (36.9%), t852 (14.3%), t924 (13.1%), t790 (11.9%), t064 (10.7%), t037 (9.5%), and t084 (3.6%). Of the 12 isolates carrying the *pvl* gene, eight (66.7%) belonged to t852 and four (33.3%) belonged to t790. All the HLMUPR-MRSA strains belonged to the t064 *spa* type while isolates with a LLMUPR belonged to t790 (10 isolates), t084 (three isolates) and t064 (nine isolate) *spa* types.

The findings revealed that *spa* types circulating in hospital A were t388 (11 isolates), t852 (four isolates), and t064, t790 and t084 (two isolates each). Those circulating in hospital B were t388 and t037 (five isolates each), t790 and t924 (three isolates each), and t064 (two isolates) \[[Figure 2](#f2){ref-type="fig"}\]. Circulating clones in hospital C were t924 (six isolates), t852 and t790 (three isolates each), t388 and t064 (one isolate each). Circulating clones in hospital D were t388 (six isolates), t852 (five isolates), and t084 (one isolate). The *spa* types detected in hospital E were t388 (eight isolates), t064 (four isolates), t037 (three isolates), t790 (two isolates), and t924 (two isolates). These *spa* types showed wide differences in the carriage of resistance and toxin genes. The characteristics related to the 84 MRSA isolates are presented in [Table 1](#t1){ref-type="table"}.

![Lane M, 100-bp DNA ladder (Fermentas, UK); lanes 1--5, the variable polymerase chain reaction products of the *spa* gene.](OMJ-D-18-00070-f2){#f2}

###### Molecular characterization of MRSA strains isolated from ICUs.

  *spa* type   SCC*mec* type   Toxin profile (n, %)               Antibiotic resistance gene profile (n, %)                                                                                                                   Antibiotic resistance profile (n, %)           n (%)
  ------------ --------------- ---------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------- -----------
  t388         III             *tst* (12, 38.7)                   *mecA* (31, 100), *ant(4´)-Ia* (25, 80.6), *aac(6´)-Ie/aph(2˝)*(18, 58.1), *aph(3´)-IIIa* (14, 45.2),*erm*(A) (9, 29.0)                                     GM (6, 19.4)                                   31 (36.9)
                                                                                                                                                                                                                              PG, CRO, RI, E, CD, T, AK, GM (10, 32.3)       
                                                                                                                                                                                                                              K, RI (2, 6.4)                                 
                                                                                                                                                                                                                              PG, CIP, K, E, CD, GM (7, 22.6)                
                                                                                                                                                                                                                              PG, CRO, CIP (6, 19.4)                         
  t852         IV              *pvl* (8, 66.7)                    *mecA* (12, 100), *ant(4´)-Ia* (8, 66.7), *erm*(B) (7, 58.3), *msr*(A) (5, 41.7)                                                                            CRO, K, RI, T, AK (3, 25.0)                    12 (14.3)
                                                                                                                                                                                                                              PG, CIP, K, E, CD, GM (4, 33.3)                
                                                                                                                                                                                                                              GM (5, 41.7)                                   
  t924         III             *tst* (4, 36.4)                    *mecA* (11, 100), *aac(6´)-Ie/aph(2˝)* (7, 63.6), *aph(3´)-IIIa* (6, 54.5), *erm*(A) (7, 63.6), *erm*(C) (4, 36.4), *msr*(B) (5, 45.5), *tet*(M) (3;27.3)   PG, CRO, RI, E, CD, T, AK, GM (2, 18.2)        11 (13.1)
                                                                                                                                                                                                                              CRO, K, RI, T, AK (1, 9.1)                     
                                                                                                                                                                                                                              PG, CIP, K, E, CD, GM (4, 36.4)                
                                                                                                                                                                                                                              PG, CRO, CIP (3, 27.3)                         
                                                                                                                                                                                                                              PG, CRO (1, 9.1)                               
  t790         IV              *pvl* (4, 40.0), *eta* (1, 10.0)   *mecA* (10, 100), *ant(4´)-Ia* (10, 100), *aac(6´)-Ie/aph(2˝)* (9, 90.0), *aph(3´)-IIIa* (7, 70.0), *tet*(M) (6, 60.0)                                      PG, CRO, K, CIP, T, TN, MUP (6, 60.0)          10 (11.9)
                                                                                                                                                                                                                              PG, CRO, K, RI, T, SYN, MUP, E, GM (4, 40.0)   
  t064         IV                                                 *mecA* (9, 100), *ant(4´)-Ia* (9, 100), *aac(6´)-Ie/aph(2˝)* (9, 100), *erm*(C) (6, 66.7), *msr*(A) (6, 66.7), *tet*(M) (4, 44.4), *mupA* (8, 88.9)         PG, CRO, K, CIP, T, TN, MUP (4, 44.4)          9 (10.7)
                                                                                                                                                                                                                              PG, CRO, K, RI, T, SYN, MUP, E, GM (5, 55.6)   
  t037         III             *tst* (5, 62.5)                    *mecA* (8, 100), *ant(4´)-Ia* (1, 12.5), *erm*(B) (3, 37.5), *msr*(B) (3, 37.5)                                                                             PG, CRO, CIP (2, 25.0)                         8 (9.5)
                                                                                                                                                                                                                              CRO, K, RI, T, AK (1, 12.5)                    
                                                                                                                                                                                                                              No resistance (5, 62.5)                        
  t084         IV              *eta* (2, 66.7), *etb* (2, 66.7)   *mecA* (3, 100), *aac(6´)-Ie/aph(2˝)* (2, 66.7), *aph(3´)-IIIa* (3, 100), *erm*(A) (3, 100), *erm*(B) (2, 66.7)                                             PG, CIP, CD, E, SYN, MUP, TN, GM (2, 66.7)     3 (3.6)
                                                                                                                                                                                                                              PG, CIP, CD, E, SYN, MUP, TN, GM (1, 33.3)     

MRSA: methicillin-resistant S. aureus; ICUs: intensive care units; PG: penicillin; CRO: ceftriaxone; CD: clindamycin; E: erythromycin; GM: gentamicin; RI: rifampin; T: tetracycline; CIP: ciprofloxacin; K: kanamycin; SYN: quinupristin-dalfopristin; AK: amikacin; TN: tobramycin; MUP: mupirocin.

Discussion
==========

We made several important findings in relation to *spa* typing of MRSA strains isolated from ICUs, including detection of t388 as the predominant *spa* type and a relatively high resistance to mupirocin (26.2%), which was distributed among *spa* types t064 (nine isolates), t790 (10 isolates), and t084 (three isolates). The distribution of the *spa* types varies from one geographical region to another.^[@r5],[@r8],[@r20]^ In contrast to our finding that t388 was the predominant type of MRSA isolated from ICUs (36.9%), another study from Iran reported a low frequency of t388 (4.4%) in MRSA strains isolated from burn patients.^[@r21]^ A study from Taiwan also showed that among 157 MRSA strains isolated from blood cultures in nine medical centers, only one isolate was t388.^[@r22]^ It appears that the prevalence of this *spa* type has increased significantly over time and was successfully established as the dominate *spa* type among MRSA isolates in the hospital studied. In our study, none of the t388 strains harbored *pvl* genes, and fewer than half of isolates (38.7%) carried the *tst* gene. PVL-negative and *tst*-positive t388 strains have been reported by several investigators.^[@r21],[@r22]^

The *spa* type t852 was the second most common type among the tested isolates (14.3%). More than half of the t852 isolates carried *pvl* genes (66.7%). PVL-positive t852 strains have been described in Oman,^[@r23]^ Saudi Arabia,^[@r24]^ Qatar,^[@r25]^ and some European countries,^[@r14],[@r15]^ suggesting an increase in the transmission of this variant Persian Gulf countries.

We detected *spa* type t924 in 13.1% of tested MRSA isolates. It was also found that all t924 isolates belonged to SCC*mec* III. Similarly, a study from Poland published in 2018 of 215 isolates obtained from the airways of 107 patients with cystic fibrosis documented a low prevalence of t924.^[@r7]^ In our study, analysis of resistance genes showed that 27.2% of isolates were resistant to rifampin. A multicenter study replicated these findings.^[@r26]^

In contrast to studies which indicated SCC*mec* IV/t790 as the most common *spa* type in Iran,^[@r27]^ our study found a prevalence of this *spa* type in 11.9% of isolates. The low frequency of t790 in our study is in line with the results of studies from Kuwait^[@r14]^ and Iran.^[@r11]^ As in the results of previous studies from other countries, *spa* type t790 was found in both PVL-negative and -positive MRSA strains.^[@r28]^ It was also found that most *spa* t790 isolates belonged to SCC*mec* IV, which is in agreement with a previous study from Kuwait.^[@r14]^ All t790 MRSA isolates were resistant to mupirocin and demonstrated the LLMUPR phenotype and were positive for many antibiotic resistant genes, including *mecA* (10, 100%), *ant(*4´)-*Ia* (10, 100%), *aac*(6´)-*Ie/aph*(2˝) (9, 90%), *aph*(3´)-*IIIa* (7, 70%) and *tet*(M) (6, 60%). This finding is in accordance with a study from Ireland, which showed the presence of aminoglycoside resistant genes in the majority of their isolates.^[@r29]^

The frequency of the SCC*mec* IV/t064 strain was 10.7% in our study. Eight of nine (88.9%) MRSA strains were found to carry the *mupA* gene. One study of the clonal distribution of MRSA in Kuwait over 12 years in 13 public hospitals reported the t064 *spa* type with an HLMUPR pattern that carried different resistance genes.^[@r14]^ In line with the results of our study, this *spa* type also has been reported in Nigeria^[@r30]^ and Ireland.^[@r15]^

Another study from Iran reported multiresistant SCC*mec* III/t037 MRSA as the major *spa* type circulating in hospitalized patients in ICUs.^[@r11]^ We found that only 9.5% of isolates belonged to the t037 *spa* type. Our data showed that the t037 strains were PVL-negative, but were positive for the *tst* gene in addition to *mecA* (8; 100%), *ant*(4´)-*Ia* (1; 12.5%), *erm*(B) (3; 37.5%), and *msr(B)* (3; 37.5%). This *spa* type has been reported in Saudi Arabia, China, Iran and among hospital acquired-MRSA isolates in Europe, the United States, and other regions of Asia.^[@r14],[@r15],[@r27]^ Although t037 MRSA isolates harboring the *vanA* gene have been detected by several investigators,^[@r10],[@r31],[@r32]^ our study showed that none of the t037 isolates were resistant to vancomycin.

The t084 *spa* type was identified among the tested MRSA strains. Our study results indicate that all SCC*mec* IV/t084 strains were mupirocin resistant. This is consistent with another Iranian study, which detected SCC*mec* IV/t084 (40%) strains among hospital- and community acquired-MRSA isolates.^[@r18]^

Published evidence suggests that SCC*mec* types I, II, and III are common among hospital acquired-MRSA isolates; however, the significant features of community acquired-MRSA are SCC*mec* types IV and V.^[@r11],[@r16]^ These can act as epidemiological markers for hospital- and community acquired-MRSA differentiation.

The results of SCC*mec* typing disclosed that type III was the predominant SCC*mec* type (59.5%) associated with MDR pattern among the MRSA isolates consistent with Japoni-Nejad et al.^[@r33]^ A wide distribution of SCC*mec* type III among the isolates in the current study emphasizes the nosocomial origin of the samples. This is indicated by the broad distribution of SCC*mec* type III among our isolates.

The frequency of *erm*(A), *erm*(B), *msr*(A), *erm*(C), and *msr*(B) genes was 22.6%, 14.3%, 13.1%, 11.9%, and 9.5%, respectively. This finding is in line with Nezhad et al,^[@r6]^ who reported the *erm*(A) gene as the predominant macrolide resistance gene among MRSA strains isolated from hospitalized patients in ICUs.

Aminoglycoside resistance represents a challenge for curing serious staphylococcal infections.^[@r5]^ The most significant gene identified among the isolates of the current study was the *ant*(4´)-*Ia* gene, followed by (6´)-*Ie/aph* (2˝) (53.6%), and *aph*(3´)-*IIIa* (35.7%). This is consistent with previous studies.^[@r6],[@r34]^ Although another study demonstrated that *tet*(M) is the most common antibiotic resistance gene detected in MRSA strains (54.05%).^[@r35]^ The results of our study show a low resistance rate for *tet*(M) (15.5%) in the isolates.

Conclusion
==========

We recorded a high frequency of resistance among the specific *spa* types. Therefore, identification and screening of dominant *spa* types and SCC*mec* elements could aim to evaluate the significance of distribution of these MRSA isolates and their clonal relationships and allow selection of proper treatment protocols and successful implementation of antibiotic stewardship programs.
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